SEC Filing⚠ 9
FMTOF: 6-K · periodic report
Femto Technologies filed its 6-K with unaudited interim financials for the six months ended June 30, 2026, reporting revenue of C$488,405, up roughly 20% from C$407,921 a year earlier, driven by higher software development revenue and the first Sensera device sales (C$3,852). The company posted a net loss of C$1,749,549 (loss per share of C$1.84), versus a prior-year profit of C$21,106,751 that was inflated by a non-cash C$30.4 million warrant revaluation gain.
The balance sheet shows C$13,002,242 in cash and C$12,052,688 in working capital at June 30, 2026, down from C$15.2 million in cash at year-end, with operating cash flow of negative C$1,898,279 for the half. The MD&A contains going-concern language stating the company's ability to continue is dependent on shareholder support and access to equity or debt financing, though management believes cash on hand is sufficient for the foreseeable future.
During the period, Femto closed the acquisition of a 40% stake in Gilad R.G. Planning and Implementation of Technologies and Software 2025 Ltd. for US$250,000 cash plus 169,811 subordinate voting shares at a deemed price of US$0.589, and owes Gilad a further US$750,000 in three quarterly instalments. A US patent (D1,091,841) for the "Female Treatment Device" was also noted as granted.
Key risks flagged in the filing include dependence on a single customer for 78% of revenue (up from 64%), the Nasdaq delisting effective June 23, 2025 with shares now trading OTC as FMTOF, a prior 1-for-500 reverse split, and operational exposure to the Israel-Iran conflict, though a ceasefire has been announced.
SEC 6-K•2mo ago
